
Pharmacy technicians and Patient Group Directions — what pharmacists need to know
4 min readPublished:

Legislation has been introduced to permit registered pharmacy technicians to supply and administer medicines under Patient Group Directions (PGDs).
Here, our Head of Healthcare Richard Hough shares what pharmacists need to know from a legal perspective.
This article was originally published in the Chemist and Druggist on 29 August 2024.
What are PGDs?
PGDs are written instructions that allow healthcare professionals specified within the Human Medicines Regulations 2012 (HMRs) to supply and/or administer a medicine directly to a group of patients with an identified clinical condition. It’s a common misconception that PGDs are a form of prescribing — they make one named healthcare professional responsible for assessing a patient and supplying or administering a medicine to them. They can be useful where assessment and treatment follow a clearly predictable pattern.
Those who require treatment but fall outside the pre-defined patient group in the PGD are referred to independent prescribers for individual assessments.
PGD's have been developed by multi-professional groups with extensive expertise. After implementation, they are subject to ongoing monitoring.
Training requirements for the healthcare professional are defined in the PGD.
Who do the amended provisions apply to?
Following a UK-wide public consultation held from 18 August to 29 September 2023, the Amendments to the HMRs came into effect from 26 June 2024.
The amended provisions apply to registered pharmacy technicians across England, Wales and Scotland. However, in Northern Ireland, pharmacy technicians aren’t registered healthcare professionals. If this changes in future, a further amendment to the HMRs may be made so that they can use PGDs.
PGDs in practice — how do they work?
To practice using a PGD, healthcare professionals must have completed any training outlined in the PGD and be deemed competent and authorised by the provider organisation. They should also determine whether they have the appropriate knowledge and skills to use a relevant PGD.
Even though the law will change, there will be no immediate impact on the provision of community pharmacy services. Any updates to services would first need to be considered in negotiations between national negotiating bodies, the Government and NHS. Where agreed, the relevant service directions and specifications would then be amended.
Despite the legislation having been introduced, there’s still debate within the profession about the impact it will have. As a starting point, pharmacy technicians in Great Britain are regulated by and accountable to the General Pharmaceutical Council (GPhC). As with pharmacists, the GPhC has the authority to set standards, maintain a register, quality assure education and investigate complaints regarding pharmacy technicians. Pharmacy technicians are also required to revalidate annually.
PGDs are developed by multi-professional groups with extensive expertise and require significant time and resource to develop and implement. While it may appear odd that pharmacy technicians have been able to author PGDs but unable to follow them, it will be up to responsible pharmacists and superintendent pharmacists to consider which PGDs are suitable for use by pharmacy technicians.
Each registered pharmacy must have a responsible pharmacist whose role is to secure the safe and effective running of the registered pharmacy when it’s operational. It’s the role of the responsible pharmacist to determine exactly how PGDs operate while they’re in control of a pharmacy.
Representative organisations agree that if the role of the pharmacist in the community pharmacy setting is to develop and flourish, an extended role for pharmacy technicians is necessary. However, it appears that there is more work to be done to ensure that grassroots pharmacists are on the same page — especially given that responsible pharmacists will be key to unlocking the use of PGDs by pharmacy technicians in the community.
This a unique case of the law changing but practice not necessarily moving at the same pace.
Talk to us
Our experienced and specialist multidisciplinary pharmacy law team includes practising and former pharmacists with a unique understanding of the challenges you face.
Talk to our team by by giving us a call, sending us an email or completing our contact form below.
Meet the author
Partner, Head of Commercial & Intellectual Property, Head of Healthcare Sector
Richard Hough
Richard is a Partner. He leads our commercial and IP team as well as our healthcare sector team.
A commercial and healthcare regulatory lawyer, Richard advises clients on a broad range of commercial issues including terms of business, purchasing, supply, manufacturing, outsourcing, distribution, agency, franchising and joint venture agreements. He also provides broader business advice on issues such as data protection and e-commerce.
In his role as sector leader, Richard sets our healthcare sector strategy, leads on solutions to the issues faced by our clients and develops our sector talent pool.
Richard also works with international clients and UK businesses expanding abroad in his role as our primary contact for both the Association of European Lawyers and Eurolegal.

We’re here to
Make the difference
Trusted guidance is just a call, email or message away. With hundreds of nationally recognised experts, get in touch today to find out how we can help.
Loading form...
Related insights

Government announces £340m uplift for community pharmacy alongside rollout of prescribing powers
We break down the sector-wide impact of the Government’s funding boost and prescribing reforms.

CQC nominated individuals — legal & practical considerations for dental practices
We explore the legal and practical considerations of the nominated individual role, with a particular focus on dental practices.

Navigating CQC applications & protecting NHS GDS contracts

How the 2025 Spending Review will affect key economic sectors

Employment Rights Bill to strengthen reproductive health rights in the workplace
Workplace reproductive health rights are due to be strengthened with the introduction of the Employment Rights Bill. We look at key changes and implications for employers.

A guide to the MHRA’s new medical device post-market surveillance requirements
The Medicines and Healthcare products Regulatory Agency (MHRA) Post-market Surveillance and Vigilance regulations are designed to ensure that new technologies are as safe as possible before hitting the UK market.





